Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03890432
Other study ID # G2-0219
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 10, 2023
Est. completion date November 2023

Study information

Verified date March 2023
Source University Hospital, Geneva
Contact Claudia P. Heidegger, MD
Phone + 41 22 37 27 440
Email claudia.heidegger@hcuge.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The survival and the outcomes of critically ill patients are strongly influenced by insulin-therapy and nutritional support. The GLUCOSAFE 2 pilot study, aims to test the performance and the security of the new GLUCOSAFE 2 software, developed by the model-based medical decision support of Aalborg University (Denmark) and adapted to the clinical needs in the intensive care unit (ICU) of the Geneva University Hospital (HUG). This new device is based on a mathematical model of the glucose-insulin metabolism and attempts to give advices for better glycaemia control and nutritional therapy. The GLUCOSAFE 2 study hypothesizes that the use of the Glucosafe 2 software will allow better glycaemia ("Time-in-target") control and better achievement of nutritional energy and protein targets in comparison to the local protocols.


Recruitment information / eligibility

Status Recruiting
Enrollment 213
Est. completion date November 2023
Est. primary completion date September 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: All patients = 18 years admitted to the ICU with - An expected length of stay = 72h - At least 1 blood glucose (BG) measurement =10 mmol/l or 2 BG measurement = 8.5 mmol/l - Informed Consent signed by the subject/ legal representative, except for patients in the historical control group Exclusion Criteria: - Lack of legal consent or consent withdrawn, except for patients in the historical control group - Pregnant or breast feeding - Diabetic ketoacidosis or hyperosmolar state - Oral feeding - Fulminant hepatic failure - Medically contraindicated to receive rapidly acting insulin by intravenous (iv) infusion or iv injection

Study Design


Related Conditions & MeSH terms


Intervention

Device:
GLUCOSAFE 2
Use of GLUCOSAFE 2 software for nutrition management and insulin-therapy
Local protocol control group with routine care
Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.
Historical control group with routine care
Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.

Locations

Country Name City State
Switzerland Hôpitaux Universitaire de Genève Geneva
Switzerland Service of Intensive Care, Geneva University Hospital, Geneva

Sponsors (2)

Lead Sponsor Collaborator
HEIDEGGER CP Aalborg University

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time-in-target (range: 5.0 - 8.5 mmol/l) Time spent in the glycaemia range of 5.0 - 8.5 mmol/l per day, per patient and in the cohort During ICU stay, up to 15 days post-randomization.
Secondary Overall number of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events Overall number of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events (per patient and in the cohort) During ICU stay, up to 15 days post-randomization.
Secondary Overall percentage of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events Overall percentage of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events (per patient and in the cohort) During ICU stay, up to 15 days post-randomization.
Secondary Number of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events due to non-compliance Overall number of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events due to non-compliance (only in intervention arm) During ICU stay, up to 15 days post-randomization.
Secondary Percentage of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events due to non-compliance Percentage of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events due to non-compliance (only in intervention arm) During ICU stay, up to 15 days post-randomization.
Secondary Time to normalize blood glucose (5.0-8.5 mmol/l) Three values < 8.5 mmol/l as indicator for normalization During ICU stay, up to 15 days post-randomization.
Secondary Percentage of time in the ICU (per patient and in the cohort) with hyperglycaemia (BG > 8.5 mmol/l) Percentage of time with BG > 8.5 mmol/l before and after normalization per patient and in the cohort. During ICU stay, up to 15 days post-randomization.
Secondary Percentage of time in the ICU (per patient and in the cohort) with hyperglycaemia (BG > 8.5 mmol/l) due to non compliance Percentage of time with BG > 8.5 mmol/l before and after normalization per patient and in the cohort due to non compliance (only in the intervention arm). During ICU stay, up to 15 days post-randomization.
Secondary Number of hyperglycemic episodes after normalization (> 8.5 mmol/l) Three values < 8.5 mmol/h as indicator for normalization From normalization time during ICU stay, up to 15 days post-randomization.
Secondary Number of hyperglycemic episodes after normalization (> 8.5 mmol/l) due to non compliance Three values < 8.5 mmol/h as indicator for normalization From normalization time during ICU stay, up to 15 days post-randomization.
Secondary Number of episodes (per patient and in the cohort) where a BG measurements is not followed up within 30 minutes by a request for Glucosafe 2 advice Number of episodes (per patient and in the cohort) where a BG measurements is not followed up within 30 minutes by a request for Glucosafe 2 advice During ICU stay, up to 15 days post-randomization.
Secondary Number of episodes (per patient and in the cohort) where pumps were not set within 30 min according to Glucosafe2 advice accepted by the nurse. Number of episodes (per patient and in the cohort) when pumps were not set within 30 min according to Glucosafe2 advice accepted by the nurse. During ICU stay, up to 15 days post-randomization.
Secondary Number of advices given by GS2 which were accepted, accepted with modification, or rejected. Number of advices given by GS2 which were accepted, accepted with modification, or rejected. During ICU stay, up to 15 days post-randomization.
Secondary Frequency of daily and cumulated BG measurements per patient and in the cohort Frequency of BG measurements (per patient and in the cohort) During ICU stay, up to 15 days post-randomization.
Secondary Frequency of daily and cumulated adjustments of insulin and nutrition pump settings (per patient and in the cohort) Frequency of daily and cumulated adjustments of insulin and nutrition pump settings (per patient and in the cohort) During ICU stay, up to 15 days post-randomization.
Secondary Glycaemic variability Mean and standard deviation (SD) of blood glucose measurements. Daily maximum blood glucose difference. During ICU stay, up to 15 days post-randomization.
Secondary Protein goal achievements (80-100% of accumulated target) with a target of 1.3 g/kg of body weight per day. Percentage of proteins received per day and at the end of the ICU stay with a target of 1.3 g/kg of body weight per day. During ICU stay, up to 15 days post-randomization.
Secondary Caloric goal achievements (80-100% of the accumulated target) by indirect calorimetry (IC) or predictive formula if IC not feasible. Percentage of nutritional and non-nutritional calories received per day and at the end of the ICU stay with a target defined by IC or predictive formula if IC not feasible. During ICU stay, up to 15 days post-randomization.
Secondary Energy debt: difference between the defined energy target (80-100%, defined by IC or predictive formula) and the energy received (nutritional and non-nutritional) Per day and at the end of the ICU stay. During ICU stay, up to 15 days post-randomization.
Secondary Protein debt: difference between the defined protein target (1.3 g/kg of body weight/day) and the proteins received Per day and at the end of the ICU stay. During ICU stay, up to 15 days post-randomization.
Secondary Prediction of BG Prediction error as a function of time elapsed since last BG measurement, per patient, per cohort.measurement (per patient and per cohort). During ICU stay, up to 15 days post-randomization.
See also
  Status Clinical Trial Phase
Completed NCT04551508 - Delirium Screening 3 Methods Study
Recruiting NCT06037928 - Plasma Sodium and Sodium Administration in the ICU
Completed NCT03671447 - Enhanced Recovery After Intensive Care (ERIC) N/A
Recruiting NCT03941002 - Continuous Evaluation of Diaphragm Function N/A
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Completed NCT04239209 - Effect of Intensivist Communication on Surrogate Prognosis Interpretation N/A
Completed NCT05531305 - Longitudinal Changes in Muscle Mass After Intensive Care N/A
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Completed NCT02916004 - The Use of Nociception Flexion Reflex and Pupillary Dilatation Reflex in ICU Patients. N/A
Recruiting NCT05883137 - High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
Completed NCT04479254 - The Impact of IC-Guided Feeding Protocol on Clinical Outcomes in Critically Ill Patients (The IC-Study) N/A
Recruiting NCT04475666 - Replacing Protein Via Enteral Nutrition in Critically Ill Patients N/A
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Not yet recruiting NCT04538469 - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Withdrawn NCT04043091 - Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction N/A
Recruiting NCT02989051 - Fluid Restriction Keeps Children Dry Phase 2/Phase 3
Recruiting NCT02922998 - CD64 and Antibiotics in Human Sepsis N/A
Completed NCT02899208 - Can an Actigraph be Used to Predict Physical Function in Intensive Care Patients? N/A
Completed NCT03048487 - Protein Consumption in Critically Ill Patients
Recruiting NCT02163109 - Oxygen Consumption in Critical Illness